NASDAQ:TXMD - TherapeuticsMD Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.18 +0.10 (+3.25 %) (As of 05/26/2019 06:56 AM ET)Previous Close$3.18Today's Range$3.10 - $3.3252-Week Range$3.00 - $7.66Volume2.31 million shsAverage Volume3.02 million shsMarket Capitalization$767.09 millionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TherapeuticsMD, Inc. operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Receive TXMD News and Ratings via Email Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webhttp://www.therapeuticsmd.com/ Phone561-961-1900Debt Debt-to-Equity Ratio1.26 Current Ratio3.39 Quick Ratio3.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.10 million Price / Sales47.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book12.72Profitability EPS (Most Recent Fiscal Year)($0.59) Net Income$-132,620,000.00 Net Margins-907.71% Return on Equity-159.71% Return on Assets-73.63%Miscellaneous Employees241 Outstanding Shares241,222,000Market Cap$767.09 million Next Earnings Date7/29/2019 (Estimated) OptionableOptionable TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." How were TherapeuticsMD's earnings last quarter? TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings data on Monday, May, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.01. The company earned $3.95 million during the quarter, compared to analysts' expectations of $5.96 million. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The business's revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted ($0.11) earnings per share. View TherapeuticsMD's Earnings History. When is TherapeuticsMD's next earnings date? TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Monday, July 29th 2019. View Earnings Estimates for TherapeuticsMD. What price target have analysts set for TXMD? 5 analysts have issued 1 year price objectives for TherapeuticsMD's shares. Their forecasts range from $4.00 to $27.00. On average, they anticipate TherapeuticsMD's stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 334.0% from the stock's current price. View Analyst Price Targets for TherapeuticsMD. What is the consensus analysts' recommendation for TherapeuticsMD? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD. What are Wall Street analysts saying about TherapeuticsMD stock? Here are some recent quotes from research analysts about TherapeuticsMD stock: 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (5/14/2019) 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019) Has TherapeuticsMD been receiving favorable news coverage? Headlines about TXMD stock have trended positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TherapeuticsMD earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. Are investors shorting TherapeuticsMD? TherapeuticsMD saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 79,298,575 shares, an increase of 2.5% from the April 15th total of 77,395,690 shares. Based on an average daily trading volume, of 2,760,062 shares, the short-interest ratio is presently 28.7 days. Approximately 39.9% of the company's shares are sold short. View TherapeuticsMD's Current Options Chain. Who are some of TherapeuticsMD's key competitors? Some companies that are related to TherapeuticsMD include FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO), Amneal Pharmaceuticals (AMRX), Uniqure (QURE), PTC Therapeutics (PTCT), Myokardia (MYOK), Arrowhead Pharmaceuticals (ARWR) and Ligand Pharmaceuticals (LGND). What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), NVIDIA (NVDA), bluebird bio (BLUE), CannTrust (CNTTF), Horizon Therapeutics (HZNP), Synergy Pharmaceuticals (SGYP) and Global Blood Therapeutics (GBT). Who are TherapeuticsMD's key executives? TherapeuticsMD's management team includes the folowing people: Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53) Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by many different of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (8.47%), FMR LLC (7.54%), BlackRock Inc. (6.39%), Daruma Capital Management LLC (2.95%), Frontier Capital Management Co. LLC (2.43%) and Rubric Capital Management LP (1.94%). Company insiders that own TherapeuticsMD stock include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD. Which major investors are selling TherapeuticsMD stock? TXMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., First Eagle Investment Management LLC, Morgan Stanley, Sanders Morris Harris LLC, 1492 Capital Management LLC, TD Asset Management Inc., Oppenheimer & Co. Inc. and Jane Street Group LLC. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD. Which major investors are buying TherapeuticsMD stock? TXMD stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Rubric Capital Management LP, Daruma Capital Management LLC, JPMorgan Chase & Co., SG Americas Securities LLC, Rice Hall James & Associates LLC, J. Goldman & Co LP and C WorldWide Group Holding A S. View Insider Buying and Selling for TherapeuticsMD. How do I buy shares of TherapeuticsMD? Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $3.18. How big of a company is TherapeuticsMD? TherapeuticsMD has a market capitalization of $767.09 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe. What is TherapeuticsMD's official website? The official website for TherapeuticsMD is http://www.therapeuticsmd.com/. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at sharehold[email protected] MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 293 (Vote Outperform)Underperform Votes: 246 (Vote Underperform)Total Votes: 539MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Why is Cost of Capital Important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.